How Stress and Cortisol Affect Gut Health and GLP-1 Signaling

Quick Answer: Does stress lower GLP-1?

Probably, but it is not proven in people. In cell and animal studies, glucocorticoids reduce the gene expression that produces GLP-1 in intestinal L-cells, which is a clear and well-mapped mechanism. Those studies used corticosteroid drugs at pharmacological doses, not everyday stress, and the effect has not been demonstrated in humans under ordinary stress. There is even human evidence pointing the other way in some settings, such as inflammation, where GLP-1 rises. What can be said with more confidence is that GLP-1 release depends on short-chain fatty acids from fiber-fermenting gut bacteria, and chronic stress is associated with fewer of those bacteria. So the honest summary is: a plausible pathway, supported by mechanism, not yet confirmed as an everyday human effect. Fiber, sleep, and regular meal timing support that pathway; no supplement has been shown to restore GLP-1 signaling in people under stress.

GLP-1 is the gut hormone that tells your brain you have had enough. It is made by L-cells in the intestinal wall, and it is the same pathway that drugs like semaglutide act on. A common claim in the microbiome world is that stress shuts this signal down. The mechanism is real and worth understanding. In humans, though, it is less settled than it first appears, and knowing exactly where the evidence ends is the useful part.

This is part of our GLP-1 Series. If you want the appetite and cravings side of this story, how stress drives sugar cravings and reward eating, we cover that separately in Cortisol, Cravings, and GLP-1. This post stays on the biology: what happens to the GLP-1 signal itself.

How Cortisol Affects GLP-1: What the Evidence Actually Shows

Chronic stress activates the HPA axis and raises cortisol. Cortisol's job is to mobilize quick energy, which is useful in a short emergency and less useful as a permanent state. The question is what that does to GLP-1.

The mechanism is genuinely elegant, and it is worth knowing exactly what it rests on. GLP-1 is cut from a precursor protein called proglucagon, encoded by the GCG gene. In L-cell lines, glucocorticoids reduce proglucagon at both the mRNA and protein level and reduce GLP-1 release, an effect blocked by a glucocorticoid-receptor blocker. Give dexamethasone or budesonide to mice, and ileal proglucagon mRNA falls and glucose-stimulated GLP-1 secretion drops (Sato et al., 2015). So glucocorticoids can suppress the GLP-1 signal at its source. (Cell and animal study).

There is an important qualifier. That study used corticosteroid drugs at anti-inflammatory doses. That is a different exposure from the cortisol your body makes during a stressful month at work. Whether ordinary chronic stress produces the same effect in people has not been shown. And the picture is not one-directional: in a human study of surgical inflammation, circulating GLP-1 roughly doubled, with cortisol among the predictors. A broad review of glucocorticoids and appetite hormones (Kuckuck et al., 2023) treats this as an active question rather than a closed one, and repeatedly flags the gaps in human data. (Review).

How Stress Affects the Gut Microbiome

Stress reaches the gut, and the clearest evidence for that comes from animals. In mice, exposure to a social stressor changed the structure of the intestinal microbial community, reduced beneficial groups, and shifted immune signaling (Bailey et al., 2011). (Animal study). In humans, the pattern is consistent but the causal picture is looser: high stress and poor sleep are associated with lower microbial diversity and fewer short-chain fatty acid producers.

What tends to be reported under chronic stress, and how confident we should be about each:

• Fewer SCFA-producing bacteria. Reasonably consistent across animal and human observational work. This is the one that matters most here, because SCFAs are the link to GLP-1.

• Weaker mucosal barrier. Clear in animals. In healthy humans, reviews of stress and intestinal permeability have not found consistent evidence, so this should not be stated as established.

• More inflammatory signaling. Supported, though it travels with the two above rather than standing alone.

• Disrupted microbial daily rhythms. Demonstrated in animals, and tied more to disrupted feeding and sleep timing than to cortisol itself.

Where this connects back to GLP-1: L-cells release GLP-1 partly in response to short-chain fatty acids arriving from the colon. Fewer SCFA producers means less of that stimulus. This is the most defensible route from stress to a weaker GLP-1 signal, and notably it does not require cortisol to act on the L-cell at all.

SCFAs and GLP-1: The Mechanism, and Its Limits

This is the best-characterized part of the whole chain. When gut bacteria ferment fiber, they produce short-chain fatty acids, mainly acetate, propionate, and butyrate. These bind FFAR2 (and FFAR3) receptors on intestinal L-cells, and that binding triggers GLP-1 secretion. The landmark work here showed that short-chain fatty acids stimulate GLP-1 release through FFAR2, in cell systems and in mice (Tolhurst et al., 2012). (Cell and animal study).

That is a mechanism, not a human outcome, and the distinction matters. In people, diets high in fermentable fiber are associated with higher GLP-1, but researchers are still working out how much of that runs through SCFA receptors and how much through other routes. Nobody has shown that raising your butyrate fixes a stress-blunted GLP-1 signal in humans.

What follows from it is unglamorous and still worth doing. Feed the bacteria that make short-chain fatty acids, and you are supporting the input that L-cells respond to. In practice that means fermentable fibers such as inulin, GOS, and FOS; resistant starch from oats, cooled potatoes, plantains, and green banana flour; and polyphenol-rich foods such as berries, cocoa, pomegranate, and green tea.

Where Akkermansia Fits: What Human Trials Show

Akkermansia muciniphila is a mucus-layer specialist, and the mechanistic case for it is strong: in mice, it supports the mucus layer and gut barrier, and a purified membrane protein from it (Amuc_1100) improves metabolism (Plovier et al., 2017). (Animal study). Worth noting, since it is often glossed over: in that study the pasteurized bacterium outperformed the live one.

It is sometimes said that Akkermansia stabilizes GLP-1 sensitivity and reduces inflammation-driven cravings. That goes beyond what has been shown. There is no trial showing Akkermansia reduces cravings in people. But the real human evidence is more interesting than the overclaim, and it is worth stating precisely.

In a proof-of-concept human trial, three months of supplementation with pasteurized Akkermansia was safe and well tolerated and improved insulin sensitivity (Depommier et al., 2019). (Human trial, small). A larger multicenter trial in people with metabolic syndrome then found something directly relevant to this page: pasteurized Akkermansia increased GLP-1. It is important to report the rest of that result honestly, though. The trial's primary insulin-sensitivity endpoint was null across the whole group, with benefits appearing in subgroups such as people with low baseline Akkermansia and those with prediabetes (Suenaert et al., 2026). (Human trial).

So: there is genuine human evidence that Akkermansia can raise GLP-1. There is no human evidence that it controls cravings, and the broader metabolic benefits were not universal. That is the accurate version, and it is a better sentence than the one it replaces.

Supporting the Pathway: What Actually Helps

Nothing here is a quick fix, and none of it replaces medical care. These are the low-risk habits that support the SCFA-to-GLP-1 pathway described above, and they are the same basics that steady cortisol.

• Eat for your SCFA producers. Fermentable fiber, resistant starch, and polyphenol-rich plants are the raw material for the short-chain fatty acids that L-cells respond to. This is the most direct lever on this page.

• Keep sleep and meal timing regular. Consistent sleep and a steady daytime eating window support the microbial rhythms that both cortisol and GLP-1 sit inside.

• Get morning light. It helps anchor the cortisol rhythm, which is upstream of everything else here.

• Give the stress response somewhere to go. Slow breathing, walking, and time outdoors help regulate the system that raises cortisol in the first place.

For the appetite and craving side of these habits, including why stress pushes people toward sugar and what to do about it, see our companion post on cortisol and cravings.

Where a Supplement Fits

Fiber, sleep, and meal timing come first, and a supplement does not replace them. If you want to add one on top of that foundation, Boost Synergy pairs Akkermansia muciniphila, the mucus-layer species discussed above, with Clostridium butyricum, a butyrate producer, alongside prebiotic fiber. The intent is to support the same SCFA and gut-barrier pathways described in this article.

What it is not: a replacement for a GLP-1 medication, and not a treatment for stress, appetite, or any medical condition. Human evidence that Akkermansia raises GLP-1 exists, as described above, but the metabolic benefits in that trial were not universal, and some people will notice nothing. Speak with a healthcare professional before starting any supplement, particularly if you are managing a condition or taking medication, including a GLP-1 receptor agonist.

Related Reading

GLP-1 & The Gut: How the Microbiome Controls Appetite & Metabolism (Blog 1)
Natural GLP-1 Support: Fiber, SCFAs, Akkermansia & Prebiotics (Blog 2)

Frequently Asked Questions

1. Does cortisol actually suppress GLP-1?

In cell and animal studies, yes: glucocorticoids reduce the gene expression behind GLP-1 in intestinal L-cells and lower GLP-1 release. But those studies used corticosteroid drugs at pharmacological doses. Whether everyday stress does the same thing in people has not been demonstrated, so this is best read as a plausible mechanism rather than an established human effect.

2. What are L-cells, and why do they matter here?

L-cells are hormone-producing cells scattered through the lining of your intestine. They are where GLP-1 is made, cut from a precursor protein called proglucagon. They matter because they are the point where diet, gut bacteria, and stress hormones all converge on the same signal.

3. How do short-chain fatty acids trigger GLP-1?

When gut bacteria ferment fiber, they produce short-chain fatty acids such as butyrate and propionate. These bind FFAR2 receptors on L-cells, which prompts GLP-1 release. This was shown in cell systems and mice, so it is a well-mapped mechanism, though how much of the human fiber-to-GLP-1 effect runs through this exact route is still being worked out.

4. Has Akkermansia been shown to raise GLP-1 in humans?

Yes, in one larger human trial pasteurized Akkermansia increased GLP-1 in people with metabolic syndrome. The same trial's main insulin-sensitivity endpoint was null for the group as a whole, with benefits concentrated in subgroups, so the honest reading is that the GLP-1 finding is real but the overall metabolic picture is mixed.

5. Is a probiotic a natural alternative to a GLP-1 medication?

No. GLP-1 receptor agonist medications work by directly activating the GLP-1 receptor at pharmacological levels. A probiotic, at best, supports the gut's own signaling inputs. These are not the same thing and should not be compared as though they are. If you are considering or taking a GLP-1 medication, that is a conversation for your clinician.

6. Does stress affect GLP-1 through the microbiome rather than directly?

That may be the more defensible route. L-cells release GLP-1 partly in response to short-chain fatty acids from gut bacteria, and chronic stress is associated with fewer of the bacteria that produce them. That path from stress to a weaker GLP-1 signal does not require cortisol to act on the L-cell at all.

7. What is the most useful thing to change first?

Fiber. It is the single most direct input to the pathway described here, it feeds the bacteria that make short-chain fatty acids, and unlike most of this topic it does not depend on unsettled science. Regular sleep and meal timing come next.

Scientific References:

1. Sato T, Hayashi H, Hiratsuka M, Hirasawa N.
   Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells
   Molecular and Cellular Endocrinology 2015;406:60-67 doi:10.1016/j.mce.2015.02.014 (Cell line and mouse study, using pharmacological glucocorticoid doses)

2. Kuckuck S, van der Valk ES, Scheurink AJW, et al.
   Glucocorticoids, stress and eating: The mediating role of appetite-regulating hormones
   Obesity Reviews 2023;24(3):e13539
   doi:10.1111/obr.13539 (Review)

3. Tolhurst G, Heffron H, Lam YS, et al.
   Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2
   Diabetes 2012;61(2):364-371
   doi:10.2337/db11-1019. (Cell and animal study)

4. Bailey MT, Dowd SE, Galley JD, et al.
   Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation
   Brain, Behavior, and Immunity 2011;25(3):397-407
   doi:10.1016/j.bbi.2010.10.023 (Animal study)

5. Plovier H, Everard A, Druart C, et al.
   A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
   Nature Medicine 2017;23(1):107-113
   doi:10.1038/nm.4236 (Animal study)

6. Depommier C, Everard A, Druart C, et al.
   Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
   Nature Medicine 2019;25(7):1096-1103
   doi:10.1038/s41591-019-0495-2 (Human trial, small)

7. Suenaert P, Segers A, Rymenans L, et al.
   Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome
   Gut Microbes 2026;18(1):2690689
   doi:10.1080/19490976.2026.2690689 (Human trial)

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions

• Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

Active Ulcerative Colitis (Inflammatory Bowel Disease)

Hyperoxaluria (Oxalate Metabolism Disorder)

Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Medical Disclaimer

This content is for educational and informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not a substitute for prescription medication or professional care, including GLP-1 receptor agonist medications. Consult a qualified healthcare professional before making changes to your diet, supplement routine, or treatment, especially if you are pregnant, nursing, managing a health condition, or taking medication.